Quantitative imaging of disease signatures through radioactive decay signal conversion
- 8 September 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 19 (10), 1345-1350
- https://doi.org/10.1038/nm.3323
Abstract
In the era of personalized medicine there is an urgent need for in vivo techniques able to sensitively detect and quantify molecular activities. Sensitive imaging of gamma rays is widely used, but radioactive decay is a physical constant and signal is independent of biological interactions. Here we introduce a framework of novel targeted and activatable probes excited by a nuclear decay-derived signal to identify and measure molecular signatures of disease. This was accomplished utilizing Cerenkov luminescence (CL), the light produced by β-emitting radionuclides such as clinical positron emission tomography (PET) tracers. Disease markers were detected using nanoparticles to produce secondary Cerenkov-induced fluorescence. This approach reduces background signal compared to conventional fluorescence imaging. In addition to information from a PET scan, we demonstrate novel medical utility by quantitatively determining prognostically relevant enzymatic activity. This technique can be applied to monitor other markers and facilitates a shift towards activatable nuclear medicine agents.Keywords
This publication has 33 references indexed in Scilit:
- Endoscopic imaging of Cerenkov luminescenceBiomedical Optics Express, 2012
- Quantitative Modeling of Cerenkov Light Production Efficiency from Medical RadionuclidesPLOS ONE, 2012
- Cerenkov Radiation Energy Transfer (CRET) Imaging: A Novel Method for Optical Imaging of PET Isotopes in Biological SystemsPLOS ONE, 2010
- Cerenkov Luminescence Imaging of Medical IsotopesJournal of Nuclear Medicine, 2010
- Radiation‐Luminescence‐Excited Quantum Dots for in vivo Multiplexed Optical ImagingSmall, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerCancer Cell, 2010
- Molecular Optical Imaging with Radioactive ProbesPLOS ONE, 2010
- Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-TrastuzumabPLOS ONE, 2010
- Standardized methods for the production of high specific-activity zirconium-89Nuclear Medicine and Biology, 2009
- Optical imaging of Cerenkov light generation from positron-emitting radiotracersPhysics in Medicine & Biology, 2009